Published in Infect Immun on May 01, 1978
Clostridium difficile: its disease and toxins. Clin Microbiol Rev (1988) 7.26
Purification and characterization of toxins A and B of Clostridium difficile. Infect Immun (1982) 6.88
Effects of Clostridium difficile toxins given intragastrically to animals. Infect Immun (1985) 5.44
Comparison of two toxins produced by Clostridium difficile. Infect Immun (1981) 5.16
Production of Clostridium difficile antitoxin. Infect Immun (1980) 3.95
Enzyme-linked immunosorbent assay for Clostridium difficile toxin A. J Clin Microbiol (1983) 3.40
Comparison of nine commercially available Clostridium difficile toxin detection assays, a real-time PCR assay for C. difficile tcdB, and a glutamate dehydrogenase detection assay to cytotoxin testing and cytotoxigenic culture methods. J Clin Microbiol (2009) 3.18
Investigation of an outbreak of antibiotic-associated colitis by various typing methods. J Clin Microbiol (1982) 2.86
Purification and characterization of Clostridium difficile toxin. Infect Immun (1979) 2.71
Transferable tetracycline resistance in Clostridium difficile. Antimicrob Agents Chemother (1981) 2.56
Neutralization of Clostridium difficile toxin by Clostridium sordellii antitoxins. Infect Immun (1978) 2.39
Identification of toxigenic Clostridium difficile by counterimmunoelectrophoresis. J Clin Microbiol (1980) 2.24
Clostridium difficile: clinical disease and diagnosis. Clin Microbiol Rev (1993) 2.19
Clostridium difficile in gnotobiotic mice. Infect Immun (1980) 2.17
Production of antitoxins to two toxins of Clostridium difficile and immunological comparison of the toxins by cross-neutralization studies. Infect Immun (1982) 2.14
Diagnosis of Clostridium difficile infection: an ongoing conundrum for clinicians and for clinical laboratories. Clin Microbiol Rev (2013) 1.85
Problems associated with counterimmunoelectrophoresis assays for detecting Clostridium difficile toxin. J Clin Microbiol (1982) 1.75
Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection. Infect Immun (1998) 1.63
Bile acid recognition by the Clostridium difficile germinant receptor, CspC, is important for establishing infection. PLoS Pathog (2013) 1.55
Importance of Glutamate Dehydrogenase (GDH) in Clostridium difficile Colonization In Vivo. PLoS One (2016) 1.40
Mucosal damage mediated by clostridial toxin in experimental clindamycin-associated colitis. Gut (1980) 1.37
Evaluation of eight cephalosporins in hamster colitis model. Antimicrob Agents Chemother (1981) 1.35
Predominant Staphylococcus aureus isolated from antibiotic-associated diarrhea is clinically relevant and produces enterotoxin A and the bicomponent toxin LukE-lukD. J Clin Microbiol (1999) 1.26
Variations in TcdB activity and the hypervirulence of emerging strains of Clostridium difficile. PLoS Pathog (2010) 1.26
Intoxication of cultured human lung fibroblasts with Clostridium difficile toxin. Infect Immun (1981) 1.19
Prediction tools for unfavourable outcomes in Clostridium difficile infection: a systematic review. PLoS One (2012) 1.19
Models for the study of Clostridium difficile infection. Gut Microbes (2012) 1.16
Prevention of clindamycin-induced mortality in hamsters by Saccharomyces boulardii. Antimicrob Agents Chemother (1984) 1.14
The enterotoxicity of Clostridium difficile toxins. Toxins (Basel) (2010) 1.07
Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters. Antimicrob Agents Chemother (2008) 1.05
Conserved oligopeptide permeases modulate sporulation initiation in Clostridium difficile. Infect Immun (2014) 1.03
Rapid stool-based diagnosis of Clostridium difficile infection by real-time PCR in a children's hospital. J Clin Microbiol (2011) 1.01
Isolation of Clostridium difficile from hospitalized patients without antibiotic-associated diarrhea or colitis. J Clin Microbiol (1982) 1.00
Ultrastructural changes of cultured human amnion cells by Clostridiu difficile toxin. Infect Immun (1979) 0.99
Variations in virulence and molecular biology among emerging strains of Clostridium difficile. Microbiol Mol Biol Rev (2013) 0.99
Etiology of tetracycline-associated pseudomembranous colitis in hamsters. Antimicrob Agents Chemother (1979) 0.95
Cecal toxin(s) from guinea pigs with clindamycin-associated colitis, neutralized by Clostridium sordellii antitoxin. Infect Immun (1980) 0.92
Factors influencing the phagocytosis of Clostridium difficile by human polymorphonuclear leukocytes. Infect Immun (1987) 0.88
Loss of surface fibronectin from human lung fibroblasts exposed to cytotoxin from Clostridium difficile. Infect Immun (1983) 0.87
A novel regulator controls Clostridium difficile sporulation, motility and toxin production. Mol Microbiol (2016) 0.85
Fixation of Clostridium difficile toxin A and cholera toxin to intestinal brush border membranes from axenic and conventional mice. Infect Immun (1989) 0.83
Antimicrobial agent-associated colitis and diarrhea. West J Med (1980) 0.81
Using phenotype microarrays to determine culture conditions that induce or repress toxin production by Clostridium difficile and other microorganisms. PLoS One (2013) 0.79
The effect of polydextrose and probiotic lactobacilli in a Clostridium difficile-infected human colonic model. Microb Ecol Health Dis (2015) 0.78
The Clostridium difficile Dlt Pathway Is Controlled by the Extracytoplasmic Function Sigma Factor σV in Response to Lysozyme. Infect Immun (2016) 0.77
A New Lab Developed Real Time PCR Assay for Direct Detection of C. Difficle from Stool Sample without DNA Extraction. Int J Biomed Sci (2016) 0.75
Collateral damage during antibiotic treatment of C. difficile infection in the aged host: insights into why recurrent disease happens. Gut Microbes (2017) 0.75
Production of vascular permeability factor by enterotoxigenic Escherichia coli isolated from man. Infect Immun (1973) 9.99
Undescribed toxin in pseudomembranous colitis. Br Med J (1977) 4.31
Pseudomembranous enterocolitis (antibiotic-related colitis). Adv Intern Med (1977) 2.73
Fatal enterocolitis in hamsters given lincomycin hydrochloride. Lab Anim Care (1968) 2.17
Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med (1978) 14.65
Plasmid-controlled colonization factor associated with virulence in Esherichia coli enterotoxigenic for humans. Infect Immun (1975) 14.65
Tularemia as a biological weapon: medical and public health management. JAMA (2001) 13.23
Production of vascular permeability factor by enterotoxigenic Escherichia coli isolated from man. Infect Immun (1973) 9.99
Botulinum toxin as a biological weapon: medical and public health management. JAMA (2001) 9.18
Susceptibility of anaerobes to cefoxitin and other cephalosporins. Antimicrob Agents Chemother (1975) 8.86
In vitro activity of thienamycin. Antimicrob Agents Chemother (1978) 8.76
Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA (2000) 8.45
Anaerobic infections. 1. N Engl J Med (1974) 8.02
Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA (1999) 7.96
Clindamycin-associated colitis due to a toxin-producing species of Clostridium in hamsters. J Infect Dis (1977) 7.68
Enterotoxigenic Escherichia coli isolated from patients with severe cholera-like disease. J Infect Dis (1971) 7.10
Anthrax as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA (1999) 7.06
In vitro activity of LY127935. Antimicrob Agents Chemother (1979) 7.01
Acute undifferentiated human diarrhea in the tropics. I. Alterations in intestinal micrflora. J Clin Invest (1971) 6.23
Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis. Gastroenterology (1978) 5.91
Toxigenic Escherichia coli: a cause of infantile diarrhea in Chicago. N Engl J Med (1972) 5.45
Treating diarrhoea. BMJ (1997) 5.22
Travelers' diarrhea and toxigenic Escherichia coli. N Engl J Med (1975) 5.20
Comparison of two toxins produced by Clostridium difficile. Infect Immun (1981) 5.16
Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity. J Virol (1989) 5.15
Polymyxin B-Induced Release of Low-Molecular-Weight, Heat-Labile Enterotoxin from Escherichia coli. Infect Immun (1974) 4.79
Glanders in a military research microbiologist. N Engl J Med (2001) 4.77
Clostridium difficile colitis: an efficient clinical approach to diagnosis. Ann Intern Med (1995) 4.42
Cytotoxicity assay in antibiotic-associated colitis. J Infect Dis (1979) 4.39
Identification of enterotoxigenic Escherichia coli and serum antitoxin activity by the vascular permeability factor assay. Infect Immun (1973) 4.07
Isolation rates and toxigenic potential of Clostridium difficile isolates from various patient populations. Gastroenterology (1981) 4.04
Experimental intra-abdominal abscesses in rats: development of an experimental model. Infect Immun (1974) 3.91
In vitro activity of N-formimidoyl thienamycin (MK0787). Antimicrob Agents Chemother (1980) 3.90
Clinical and laboratory observations in Clostridium difficile colitis. Am J Clin Nutr (1980) 3.89
Intestinal microflora. Gastroenterology (1971) 3.86
Intestinal flora in health and disease. Gastroenterology (1984) 3.84
Susceptibility of the Bacteroides fragilis group in the United States in 1981. Antimicrob Agents Chemother (1983) 3.83
Quantitative bacteriology of the vaginal flora. J Infect Dis (1977) 3.81
Principles of appropriate antibiotic use for acute pharyngitis in adults: background. Ann Intern Med (2001) 3.75
Studies of intestinal microflora. II. Microorganisms of the small intestine and their relations to oral and fecal flora. Gastroenterology (1967) 3.71
Management of anaerobic infections. Ann Intern Med (1975) 3.62
The capsular polysaccharide of Bacteroides fragilis as a virulence factor: comparison of the pathogenic potential of encapsulated and unencapsulated strains. J Infect Dis (1977) 3.62
Studies of intestinal microflora. I. Effects of diet, age, and periodic sampling on numbers of fecal microorganisms in man. Gastroenterology (1967) 3.60
Rapid diagnosis of anaerobic infections by direct gas-liquid chromatography of clinical speciments. J Clin Invest (1976) 3.34
Anaerobic pleuropulmonary infections. Medicine (Baltimore) (1972) 3.30
Microbial synergy in experimental intra-abdominal abscess. Infect Immun (1976) 3.21
Abdominal trauma, anaerobes, and antibiotics. Surg Gynecol Obstet (1973) 3.18
Anaerobic infections (second of three parts). N Engl J Med (1974) 3.18
Principles of appropriate antibiotic use for acute rhinosinusitis in adults: background. Ann Intern Med (2001) 3.15
Colitis induced by Clostridium difficile. Rev Infect Dis (1980) 3.15
Anaerobic infections (third of three parts). N Engl J Med (1974) 3.13
Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120. J Virol (1992) 3.13
Does OKT3 monoclonal antibody react with an antigen-recognition structure on human T cells? Proc Natl Acad Sci U S A (1981) 3.09
Intestinal fluid and electrolyte transport in human cholera. J Clin Invest (1970) 3.09
Enzyme immunoassays for detection of Clostridium difficile toxins A and B in fecal specimens. J Infect Dis (1984) 3.07
Treatment of anaerobic infections with lincomycin and clindamycin. N Engl J Med (1972) 3.05
Studies on enterotoxin from Escherichia coli associated with acute diarrhea in man. J Lab Clin Med (1971) 3.03
Antibiotic-associated pseudomembranous colitis. Rev Infect Dis (1980) 3.02
Oral vancomycin for antibiotic-associated pseudomembranous colitis. Lancet (1978) 2.87
Cultures for Clostridium difficile in stools containing a cytotoxin neutralized by Clostridium sordellii antitoxin. J Clin Microbiol (1979) 2.86
Structural features of polysaccharides that induce intra-abdominal abscesses. Science (1993) 2.86
Survival of Lactobacillus species (strain GG) in human gastrointestinal tract. Dig Dis Sci (1992) 2.78
Inactivation of cephalosporins by Bacteroides. Antimicrob Agents Chemother (1979) 2.75
Pseudomembranous enterocolitis (antibiotic-related colitis). Adv Intern Med (1977) 2.73
Antimicrobial susceptibilities of 1,292 isolates of the Bacteroides fragilis group in the United States: comparison of 1981 with 1982. Antimicrob Agents Chemother (1984) 2.71
Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody. Proc Natl Acad Sci U S A (1991) 2.71
Symptomatic relapse after oral vancomycin therapy of antibiotic-associated pseudomembranous colitis. Gastroenterology (1980) 2.60
Hormone levels during dietary changes in premenopausal African-American women. J Natl Cancer Inst (1996) 2.59
Effect of preoperative neomycin-erythromycin intestinal preparation on the incidence of infectious complications following colon surgery. Ann Surg (1973) 2.57
Antimicrobial therapy of experimental intraabdominal sepsis. J Infect Dis (1975) 2.56
Stimulation of intestinal adenyl cyclase by Escherichia coli enterotoxin: comparison of strains from an infant and an adult with diarrhea. J Infect Dis (1974) 2.52
Nationwide study of the susceptibility of the Bacteroides fragilis group in the United States. Antimicrob Agents Chemother (1985) 2.47
Anaerobic infections of the lung and pleural space. Am Rev Respir Dis (1974) 2.46
Neutralization of Clostridium difficile toxin by Clostridium sordellii antitoxins. Infect Immun (1978) 2.39
Plasmid-mediated, transferable resistance to clindamycin and erythromycin in Bacteroides fragilis. J Infect Dis (1979) 2.38
Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users: plasma viral load and CD4+ cell count. JAMA (1998) 2.37
Preoperative oral antibiotics reduce septic complications of colon operations: results of prospective, randomized, double-blind clinical study. Ann Surg (1977) 2.36
Production of experimental ulcerative colitis in gnotobiotic guinea pigs with simplified microflora. Infect Immun (1981) 2.34